BR112022016326A2 - Anticorpo anti-il-2, e fragmento de ligação ao antígeno do mesmo e uso médico do mesmo - Google Patents

Anticorpo anti-il-2, e fragmento de ligação ao antígeno do mesmo e uso médico do mesmo

Info

Publication number
BR112022016326A2
BR112022016326A2 BR112022016326A BR112022016326A BR112022016326A2 BR 112022016326 A2 BR112022016326 A2 BR 112022016326A2 BR 112022016326 A BR112022016326 A BR 112022016326A BR 112022016326 A BR112022016326 A BR 112022016326A BR 112022016326 A2 BR112022016326 A2 BR 112022016326A2
Authority
BR
Brazil
Prior art keywords
antigen
antibody
binding fragment
medical use
complex
Prior art date
Application number
BR112022016326A
Other languages
English (en)
Inventor
Lin Yuan
Zhu Fuxiang
Liao Cheng
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai Shengdi Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of BR112022016326A2 publication Critical patent/BR112022016326A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPO ANTI-IL-2, E FRAGMENTO DE LIGAÇÃO AO ANTÍGENO DO MESMO E USO MÉDICO DO MESMO. Trata-se de um anticorpo anti-IL-2, e um fragmento de ligação ao antígeno do mesmo e o uso médico do mesmo. São fornecidos adicionalmente um complexo (incluindo uma proteína de fusão) do anticorpo anti-IL-2, o fragmento de ligação ao antígeno do mesmo e IL-2, e o uso do complexo como um fármaco para tratar doenças autoimunes e doenças inflamatórias.
BR112022016326A 2020-02-21 2021-02-19 Anticorpo anti-il-2, e fragmento de ligação ao antígeno do mesmo e uso médico do mesmo BR112022016326A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010107662 2020-02-21
PCT/CN2021/076806 WO2021164722A1 (zh) 2020-02-21 2021-02-19 抗il-2抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
BR112022016326A2 true BR112022016326A2 (pt) 2022-10-11

Family

ID=77390419

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016326A BR112022016326A2 (pt) 2020-02-21 2021-02-19 Anticorpo anti-il-2, e fragmento de ligação ao antígeno do mesmo e uso médico do mesmo

Country Status (11)

Country Link
US (1) US20230089620A1 (pt)
EP (1) EP4108683A4 (pt)
JP (1) JP2023515480A (pt)
KR (1) KR20220143869A (pt)
CN (1) CN115210257A (pt)
AU (1) AU2021223063A1 (pt)
BR (1) BR112022016326A2 (pt)
CA (1) CA3169980A1 (pt)
MX (1) MX2022010218A (pt)
TW (1) TW202140563A (pt)
WO (1) WO2021164722A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
WO2014028748A1 (en) * 2012-08-15 2014-02-20 Irm Llc Interleukin 2 antibodies and antibody complexes
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
WO2019168791A2 (en) * 2018-02-28 2019-09-06 The Board Of Trustees Of The Leland Stanford Junior University Single-chain il-2/antibody fusions that selectively activate regulatory t cells

Also Published As

Publication number Publication date
WO2021164722A1 (zh) 2021-08-26
EP4108683A4 (en) 2024-04-03
AU2021223063A1 (en) 2022-09-29
KR20220143869A (ko) 2022-10-25
CN115210257A (zh) 2022-10-18
EP4108683A1 (en) 2022-12-28
MX2022010218A (es) 2022-09-19
JP2023515480A (ja) 2023-04-13
CA3169980A1 (en) 2021-08-26
US20230089620A1 (en) 2023-03-23
TW202140563A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
EA202190903A2 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
EA201891656A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний
CL2015002686A1 (es) Muteínas de interleucina-2 para la expansion de células t reguladoras
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CO2022003156A2 (es) Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15rα y su uso
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
PE20170519A1 (es) Anticuerpos antagonistas del interferon alfa y omega
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
AR122018A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
CO2022004757A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
EA202091577A1 (ru) Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител
BR112022016326A2 (pt) Anticorpo anti-il-2, e fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
EA202190261A1 (ru) Топические маслянистые композиции
UY35457A (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA ß
EA202192488A1 (ru) Антитела против tsg-6 и их применения
BR112018015826A2 (pt) anticorpos monoclonais específicos egfl6 e métodos de seu uso
AR095387A1 (es) Proteínas específicas para el baff y para la b7rp1 y sus usos
MX2020003672A (es) Proteinas de fusion inmunomoduladora.
BR112022006177A2 (pt) Kir3dl3 é um receptor inibidor do sistema imune e do mesmo